Drug Trial Radar · NCT00002719
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Jul 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Planned (sponsor's estimate)
Start
Dec 1995
Primary completion
Nov 2001
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- First posted
- Apr 29, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 61 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in the bone marrow or peripheral blood and may help a person's immune system recover after chemotherapy and radiation therapy. Combining more than one drug and giving drugs in different ways may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without G-CSF in treating older patients with acute myeloid leukemia.
Conditions
- Leukemia
- Neutropenia
Interventions
filgrastimBiological
amsacrineDrug
carmustineDrug
cytarabineDrug
etoposideDrug
idarubicinDrug
mitoxantrone hydrochlorideDrug
peripheral blood stem cell transplantationProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Azienda Policlinico Umberto Primo
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.